3
Announcements
Trials
Browse
Landscape
Phase
Phase 1
2
Status
Recruiting
6
Active not recruiting
3
Not yet recruiting
2
Completed
2
Sponsor Class
INDUSTRY
2
Study Type
Interventional
2
Sponsor
Cancer Type
Other hematologic neoplasm
1
Lymphoid
1
Conditions
Mature B-cell Neoplasms
1
Hematologic Neoplasms
1
Interventions
Cyclophosphamide
1492
Cisplatin
1414
Paclitaxel
1317
Radiotherapy
1261
Carboplatin
1250
Gemcitabine
1215
Docetaxel
1109
Bevacizumab
1030
Fluorouracil
894
Doxorubicin
792
Dexamethasone
748
Rituximab
719
Capecitabine
716
Oxaliplatin
700
pembrolizumab
680
Etoposide
678
Irinotecan
634
Filgrastim
621
Cytarabine
586
Leucovorin
579
Nivolumab
558
Vincristine
515
Prednisone
475
Cetuximab
465
Bortezomib
459
Erlotinib Hydrochloride
456
Trastuzumab
447
Methotrexate
438
Lenalidomide
427
Pemetrexed
420
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
2 trials
Recent
Start date
Enrollment
Completed
×
Interventional
×
ARQ531
×
Clear all
NCT05673460
2026-05-13
MK-1026-002
Merck Sharp & Dohme LLC
Phase 1
Completed
7 enrolled
15 charts
NCT06586671
2024-09-19
MK-1026-007
Merck Sharp & Dohme LLC
Phase 1
Completed
40 enrolled